Discovery of imidazole vinyl pyrimidines as a novel class of kinase inhibitors which inhibit Tie-2 and are orally bioavailable
作者:David Buttar、Mike Edge、Steve C. Emery、Martina Fitzek、Cheryl Forder、Alison Griffen、Barry Hayter、Chris F. Hayward、Philip J. Hopcroft、Richard W.A. Luke、Ken Page、John Stawpert、Andy Wright
DOI:10.1016/j.bmcl.2008.06.106
日期:2008.8
Tie-2 is a receptor tyrosine kinase which is involved in angiogenesis and thereby growth of human tumours. The discovery and SAR of a novel class of imidazole-vinyl-pyrimidine kinase inhibitors, which inhibit Tie-2 in vitro is reported. Their synthesis was carried out by condensation of imidazole aldehydes with methyl pyrimidines. These compounds are lead-like, with low molecular weight, good physical properties and oral bioavailability. (C) 2008 Elsevier Ltd. All rights reserved.
ANTI-ANGIOGENETIC THERAPEUTIC AGENTS
申请人:AstraZeneca AB
公开号:EP1575963B1
公开(公告)日:2008-05-07
Therapeutic agents
申请人:Luke William Arthur Richard
公开号:US20060069109A1
公开(公告)日:2006-03-30
A compound of the Formula: (I) (A chemical formula should be inserted here—please see paper copy enclosed herewith) Formula: (I); for use as a Tie2 receptor tyrosine kinase inhibitor in a warm-blooded animal such as man.